Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and ...

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in ...

To read all of these articles and more, visit centerforbiosimilars.com.

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

The authors claimed that the ‘Biosimilar Red Tape Elimination Act (S.2305) 3 would classify all biosimilars as interchangeable, highlighting its shortcomings, and the justification that similar ...

CT-P39, also known as Omlyclo, was approved by the European Medicines Agency in May 2025 as the first omalizumab biosimilar. 2 The biosimilar was also approved by Health Canada in December 2024 and ...